Saffron Formulations

What Saffron Formulations does

Saffron Formulations Private Limited is an Ahmedabad-based pharmaceutical company founded in 2015 that manufactures and markets branded generic formulations across eight therapeutic categories — Cardiac, Central Nervous System, Gastrointestinal, Nutritional, Pain Management, Renal Care, Respiratory, and Anti-infective. The company operates a WHO GMP-accredited manufacturing facility producing tablets, ointments, capsules, liquids, and dry syrups, supported by a 24/7 automated quality control system and a centralized internet-based management platform for real-time sales, realization, outstanding, and stock visibility. Its product portfolio comprises approximately 107 SKUs sold under brand names such as Telmeron, Rafron, Vitacore, Safronac, Safrolog, and Ventocore, targeted at specialty physicians (gastroenterologists, ENTs, cardiologists, nephrologists, orthopedists) in the domestic Indian market.

The company runs a B2B go-to-market model via a Pan-India distribution network of 1 central warehouse, 14 carrying-and-forwarding agents (CFAs), 750 stockists, and over 100,000 chemist outlets, with a divisional field sales force promoting products directly to doctors, hospitals, and polyclinics. Marketing activities center on medical education and academic partnerships, including expert-curated lecture series (NEFFRON for kidney disorders, LIVER TALK for liver disease) and corporate sponsorship of national physician conferences. Pricing is not publicly disclosed and is negotiated by channel and volume rather than published list price.

Saffron Formulations is privately held, founder-led under Managing Director Amit Singh, and operates exclusively in the domestic Indian market with no disclosed international expansion, no external funding rounds, and no merger, acquisition, or restructuring activity. The company has received industry recognition including the Emerging Company Award at Indian Pharma Expo 2015, Business Excellence Award in 2017, Most Promising Pharmaceutical Company at the ICONIC HEALTHCARE SUMMIT 2022, and continued conference sponsorship through 2024.

Name

Saffron Formulations

Legal name

Saffron Formulations Private Limited

Website

https://saffronformulations.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Saffron Formulations Private Limited is an Ahmedabad-based Indian pharmaceutical company founded in 2015 that manufactures and markets approximately 107 branded generic formulations across eight therapeutic categories through a Pan-India network of 750 stockists and 100,000+ chemist outlets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Formulations

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical formulations
• Generic medicines
• Branded generics
• WHO GMP manufacturing
• Therapeutic categories

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical formulations across multiple therapeutic segments including Gastroenterology, Otolaryngology, Respiratory, Anti-Infectives, Nutrition, Pain, Renal, and Cardiac. Products are distributed through a network of C&F agents, stockists, and retailers to reach over 100,000 chemist outlets across India.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Saffron Formulations manufactures and sells approximately 107 branded generic pharmaceutical formulations across eight therapeutic categories (Cardiac, Central Nervous System, Gastrointestinal, Nutritional, Pain Management, Renal Care, Respiratory, and Anti-Infective) from its WHO GMP accredited facility. The company runs a divisional field sales force that promotes these products to doctors, hospitals, and polyclinics, with distribution through C&F agents, stockists, and retailers reaching over 100,000 chemist outlets across India.

Product overview

Saffron Formulations is a pharmaceutical company with a diversified portfolio of approximately 107 branded generic products across 8 therapeutic categories: Cardiac, Central Nervous System, Gastrointestinal, Nutritional, Pain Management, Renal Care, Respiratory, and Anti-infective. The products range from cardiovascular medications (Telmeron, Cilnaz, Safrotor), gastro treatments (Rafron, Safepraz, Sibocure, Benuliv), nutritional supplements (Vitacore, Fevimax, Calvaro), pain management (Safronac, Nervilax, Enzem), respiratory treatments (Ventocore, Bilzit), to antibiotics (Solzer, Kefdox, Kartel CV). The company operates through a divisional structure with focused teams in key markets and distributes through a Pan-India network of 1 central warehouse, 14 CFAs, and 750 stockists reaching over 100,000 chemist outlets.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiac Portfolio Cardiac medications including Anti-Hypertensives (Telmeron, Cilnaz, Prazosure XL), ARB formulations (Telmeron 20/40, Telmeron 40 AM/CH/CN/H, Telmeron Trio), Calcium channel blockers (Cilnaz 10/20), Alpha-1 blockers (Prazosure XL 2.5/5), Anti-Hyperlipidemic (Ronastin 10/20/F), and Diuretics (Safrotor 10/20/40, Safrotor Plus 10), marketed to cardiologists and physicians across India.
• Central Nervous System Portfolio CNS medications including Anti-Depressants (Itcalms 5/10/20, Itcalms Plus 5/10) and Anti-Tinnitus treatments (Tinzit - Ginkgo Biloba + GABA + Nigella Sativa), prescribed by psychiatrists, neurologists, and ENT specialists.
• Gastrointestinal Portfolio Gastro medications including Anti-Ulcerants (Rafron, Rafron DSR, Safepraz), Antibiotics (Sibocure), Corticosteroids (Rafacol), Digestive Enzymes (Dixexa, Dizexa), Hepato-Protective (Benuliv, Rafahep, Rafaliv), Laxatives (Kinlax), Probiotics (Biokraft), Prokinetics (Levanz), and IBS treatments (Mebedaz Plus), prescribed by gastroenterologists.
• Nutritional Portfolio Nutritional supplements including Calcium supplements (Calvaro), Dietary supplements (Vitacore-57, Vitacore OD), Immunity boosters (Vitacore C Plus), Iron supplements (Fevimax, Fevimax Z, Fevimax LP), and Nerve supplements (Benuvo, Benuvo Injection), supplied to physicians, hospitals, and chemists for patient use.
• Pain Management Portfolio Pain medications including Anti-Inflammatory (Safronac MR/P/SP/SR), Anti-Oedematous (Enzem, Enzem Forte, Enzem Plus), Corticosteroids (Defcon 6/30), Neuropathic Pain (Nervilax DN/M/NT/Plus SR/Trio), and combination products (Safrodol P, Safrotor Plus 10), prescribed for pain management across specialties.
• Renal Care Portfolio Renal medications including Amino Acid supplements (Safrolog, Safrolog DS), Anti-Gout preparations (Goutfree 40 XL/80XL), Anti-Hyperphosphatemic (Selvasure 400/800), and High Dose Probiotics (Biokraft 15), used by nephrologists for renal patient management.
• Respiratory Portfolio Respiratory medications including Anti-Allergic formulations (Ventocore AX/M/M Kid, Bilzit 40/M/M 40, Gemfex 120, Monzem FX) and Intranasal Corticosteroids (Ventocore Nasal Spray, Ventocore AZ Nasal Spray, Ventocore Oxy Nasal Spray), prescribed by pulmonologists, allergists, and ENT specialists.
• Anti-Infective Portfolio Anti-infective antibiotics including Kartel CV (Cefuroxime + Clavulanic Acid), Kefdox 200/CV/O (Cefpodoxime-based combinations), Solzer 1000/625 (Amoxicillin + Clavulanic Acid), and Mortega (Cefixime + Sulbactum), used by physicians for bacterial infection treatment.

Quantifiable outcome

• Entered top 150 pharmaceutical companies in India within 2 years of inception (2015)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Lupin: One of India's largest pharma majors with overlapping branded-generics presence in cardiac, respiratory, anti-infectives, and CNS. A broader incumbent that competes in many of Saffron's categories but at meaningfully larger scale and with global reach.
• Glenmark Pharmaceuticals: Indian pharma major with branded generics and specialty focus in dermatology, respiratory, and cardiac. A larger incumbent that competes in several of Saffron's segments, particularly respiratory (Ventocore overlap).
• Zydus Lifesciences (Cadila): Large Indian pharma group with broad branded-generics, biosimilars, and consumer-health businesses. Overlaps in gastro, cardiac, and anti-infective categories and represents the kind of strategic acquirer a company like Saffron could attract.

Direct peers

• Alkem Laboratories: Indian mid-to-large pharma with multi-therapeutic branded generics in gastro, cardiac, anti-infectives, and nutrition. Comparable in its focus on affordable formulations, India-first distribution model, and therapy-area specialization within a broad portfolio.
• Emcure Pharmaceuticals: Indian pharma with branded generics across cardiac, anti-infectives, CNS, and women's health. Comparable mid-scale, India-focused, multi-therapeutic formulation player with similar field-sales GTM.
• Torrent Pharmaceuticals: Indian pharma with deep specialty presence in cardiac and CNS, overlapping two of Saffron's strongest segments. Comparable in its physician-channel specialty-marketing approach and therapy-area focus.
• Mankind Pharma: One of India's largest domestic-focused pharma companies with a similarly broad branded-generics portfolio across multiple therapeutic segments. Comparable in its field-sales-driven, prescription-led GTM across cardiac, gastro, anti-infectives, and nutritional categories.
• Intas Pharmaceuticals: Privately held Indian pharma with strong specialty focus in nephrology, cardiac, and CNS — directly overlapping Saffron's renal and cardiac portfolios. Comparable as an India-first, specialty-branded-generics player at a larger scale.
• Macleods Pharmaceuticals: Privately held Indian pharma with a broad branded-generics portfolio across anti-infectives, cardiac, CNS, and gastro. Highly comparable as a privately held, India-dominant, multi-therapeutic formulation player of similar scale.
• Micro Labs: Privately held Indian pharma with a diversified branded-generics portfolio across cardiac, CNS, gastro, anti-infectives, and nutrition. Comparable multi-therapeutic, India-focused, field-sales-driven model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/saffronformulations
• LinkedInlinkedin.com/company/saffron-formulations-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saffron Formulations